Risk of Postoperative Surgical Site Infections after Vedolizumab versus Anti-Tumor Necrosis Factor Therapy: A Propensity-Score Matching Analysis in Inflammatory Bowel Disease

BACKGROUND: Perioperative vedolizumab (VDZ) and anti-tumor necrosis factor (TNFi) therapies are implicated in causing postoperative complications in inflammatory bowel disease (IBD). AIM: To compare the risk of surgical site infections (SSIs) between VDZ- and TNFi-treated IBD patients in propensity-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Aliment Pharmacol Ther
Main Authors: Park, KT, Sceats, Lindsay, Dehghan, Melody, Trickey, Amber W., Wren, Anava, Wong, Jessie J., Bensen, Rachel, Limketkai, Berkeley N., Keyashian, Kian, Kin, Cindy
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6043399/
https://ncbi.nlm.nih.gov/pubmed/29876995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14842
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados